Valuation dashboard for bioAffinity Technologies, Inc. (BIAF) with P/E N/A, P/B 0.49, EV/EBITDA -0.19 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Analysis Summary
Trailing-twelve-month margins: gross margin -39.6%, operating margin -209.8%, net margin -257.3%.
At the current price of $8.75, BIAF has negative trailing earnings (P/E not meaningful) and an ROE of -257.27%. Market capitalisation stands at $4M.
Balance sheet quality for BIAF: current ratio of 2.6. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 0.49 |
| EV / EBITDA | -0.19 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-3848.81 |
| vs Current Price | -44086.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BIAF | bioAffinity Technologies, Inc. | $4M | 0.49 | -257.3% | |
| 0R0H.L | Thermo Fisher Scientific Inc. | $244.6B | 35.47 | 4.45 | 12.6% |
| TMO | Thermo Fisher Scientific Inc. | $241.0B | 35.36 | 4.64 | 13.4% |
| 0R2B.L | Danaher Corporation | $150.1B | |||
| DHR | Danaher Corporation | $149.3B | 39.34 | 2.98 | 7.7% |
| NTRA | Natera, Inc. | $52.5B | 30.51 | -11.7% | |
| 0HAV.L | Agilent Technologies, Inc. | $47.8B | 95.79 | 6.15 | 6.4% |
| 0JDM.L | IQVIA Holdings Inc. | $45.7B |
Price
| Price | $8.75 |
| Market Cap | $4M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -257.27% |
| Return on Invested Capital | -237.93% |
| Return on Assets | -199.30% |
| Gross Margin | -39.57% |
| Operating Margin | -209.82% |
| Net Margin | -257.33% |
Related companies: ARTL · CARM · GTBP · LIPO · MNDR · PBM · PTIX
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of BIAF: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks